Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European Union marketing approval in next few months, manufacturers announced last week.
Pangenotypic treatments are suitable for all genotypes of hepatitis C. Pangenotypic products may simplify prescribing and treatment enrolment by removing the need for genotype testing and simplifying treatment. But, in settings where genotype testing is easily available, other considerations may be important for simplifying treatment, especially equal efficacy across different patient groups.
Maviret, a combination of the NS3/NS4 protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir, is recommended for approval as a treatment for hepatitis C genotypes 1-6. Maviret is manufactured by AbbVie.
Glossary
- compensated cirrhosis
The earlier stage of
cirrhosis, during which the liver is damaged but still able to perform most of
its functions. See also ‘cirrhosis’ and ‘decompensated cirrhosis’.
Clinical trials of glecaprevir/pibrentasvir showed very high rates of sustained virologic response (97.5% across genotypes 1-6) and in harder-to-treat groups of people such as those with genotype 3, severe kidney disease or compensated cirrhosis.
The second product, Vosevi, is a combination of the NS5B polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir and the NS3/NS4 protease inhibitor voxilaprevir. Like Maviret, Vosevi is dosed once-daily. Vosevi is manufactured by Gilead Sciences.
Vosevi is also recommended for approval as a treatment for hepatitis C genotypes 1-6. Clinical trials to support the approval of Vosevi showed that the combination cured 95% of people with and without cirrhosis, and 96% of people with genotype 3 infection and cirrhosis, one of the hardest patient groups to cure.
Sofosbuvir and velpatasvir are already approved as a combination product, Epclusa, for the treatment of genotypes 1-6.
Final details of the duration of treatment with each product will be available when full marketing approval is granted by the European Commission later this year. Vosevi is expected to receive US marketing approval by August 2017 and Maviret is also undergoing US review.